Cellectis SA: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Cellectis SA Unternehmen

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Cellectis SA Informationen



BörsenkürzelCLLS

Name des UnternehmensCellectis SA

IPO-datumFeb 06, 2007

CEOSourdive (David J.D)

Anzahl der mitarbeiter224

WertpapierartDepository Receipt

GeschäftsjahresendeFeb 06

Addresse8, rue de la Croix Jarry

StadtPARIS

BörseNASDAQ OMX - NASDAQ BASIC

LandFrance

Postleitzahl75013

Telefon33181691600

Websitehttps://www.cellectis.com/

BörsenkürzelCLLS

IPO-datumFeb 06, 2007

CEOSourdive (David J.D)

Führungskräfte von Cellectis SA



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Andre Choulika, Ph.D.

Chief Executive Officer, Co-Founder, Director

--

Dr. David Sourdive, Ph.D.

Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director

--

Dr. Philippe Duchateau, Ph.D.

Chief Scientific Officer

--

Mr. Pierre Bastid

Non-Executive Independent Director

--

Mr. Laurent Arthaud

Non-Executive Independent Director

--

Dr. Rainer J. Boehm, M.D.

Non-Executive Independent Director

--

Mr. Stephan Reynier

Chief Regulatory and Pharmaceutical Compliance Officer

--

Ms. Marie-Bleuenn Terrier

General Counsel

--

Mr. Arthur Stril

Chief Financial Officer and Chief Business Officer

--

Dr. Steven (Steve) Doares, Ph.D.

Senior Vice President - US Manufacturing

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Andre Choulika, Ph.D.

Chief Executive Officer, Co-Founder, Director

--

Dr. David Sourdive, Ph.D.

Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director

--

Dr. Philippe Duchateau, Ph.D.

Chief Scientific Officer

--

Mr. Pierre Bastid

Non-Executive Independent Director

--

Mr. Laurent Arthaud

Non-Executive Independent Director

--

Dr. Rainer J. Boehm, M.D.

Non-Executive Independent Director

--

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach RegionUSD

Name

Umsatz

Anteil

France

41.51M

0.00%

Other

0.00

0.00%

USA

0.00

0.00%

Nach Geschäftsbereich

Nach Region

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Sun, Jan 4

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Long Focus Capital Management LLC

5.70%

B Group, Inc.

4.54%

UBS Asset Management Switzerland AG

1.99%

BlackRock Institutional Trust Company, N.A.

0.48%

Nomura Investment Management Business Trust

0.31%

Andere

86.98%

Aktionäre

Anteil

Long Focus Capital Management LLC

5.70%

B Group, Inc.

4.54%

UBS Asset Management Switzerland AG

1.99%

BlackRock Institutional Trust Company, N.A.

0.48%

Nomura Investment Management Business Trust

0.31%

Andere

86.98%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

7.72%

Hedge Fund

6.09%

Investment Advisor/Hedge Fund

0.42%

Research Firm

0.22%

Andere

85.55%

Institutionelle Beteiligung



Aktualisiert: Mon, Dec 8

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

70

10.10M

29.55%

--

2025Q3

77

10.10M

29.65%

-3.45M

2025Q2

79

13.55M

35.05%

-1.95M

2025Q1

82

15.50M

31.47%

-7.25M

2024Q4

86

16.67M

24.79%

+2.93M

2024Q3

104

15.35M

28.39%

+1.55M

2024Q2

103

13.80M

26.34%

-48.27K

2024Q1

112

13.82M

26.53%

-5.23M

2023Q4

124

13.74M

31.43%

+147.34K

2023Q3

142

13.59M

44.11%

-2.54M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Long Focus Capital Management LLC

4.12M

5.7%

-594.03K

-12.59%

Sep 30, 2025

B Group, Inc.

3.28M

4.54%

+25.00K

+0.77%

Sep 30, 2025

UBS Asset Management Switzerland AG

1.44M

1.99%

--

Jan 31, 2025

BlackRock Institutional Trust Company, N.A.

337.45K

0.47%

+337.45K

--

Dec 31, 2025

Nomura Investment Management Business Trust

226.88K

0.31%

--

Sep 30, 2025

Bellecapital AG

226.07K

0.31%

--

Jun 30, 2025

Citadel Advisors LLC

221.96K

0.31%

+221.96K

--

Sep 30, 2025

LPL Financial LLC

85.15K

0.12%

-515.00

-0.60%

Sep 30, 2025

Morgan Stanley & Co. International Plc

83.39K

0.12%

+10.20K

+13.94%

Sep 30, 2025

Millennium Management LLC

57.74K

0.08%

+22.08K

+61.92%

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

ActivePassive International Equity ETF

0%

Avantis International Equity ETF

0%

ActivePassive International Equity ETF

Anteil0%

Avantis International Equity ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten